vaccine efficacy

Nucleoside-Modified mRNA Influenza Vaccine Prevents Symptomatic and Febrile Illness in a Human Challenge Model

A phase 2a human challenge trial found a nucleoside‑modified mRNA influenza vaccine provided complete protection against symptomatic and febrile A/H1N1 infection versus unvaccinated controls and reduced viral load versus control and QIV, wi

Pfizer’s Modified mRNA Quadrivalent Influenza Vaccine Demonstrates 34.5% Relative Efficacy vs Licensed Inactivated Vaccine in Phase 3 Trial